NASDAQ$BIOLQ

Biolase Inc · Q3 2021 earnings

Q3 2021 earnings · · Investor relations

Briefing

Reported a strong third quarter with significant revenue growth and improved gross margin, driven by rising demand for dental lasers.

BIOLASE reported a 46% increase in net revenue to $9.5 million for the third quarter of 2021, driven by strong demand for dental lasers. Gross margin improved to 51%, and the company maintained a strong cash position of $33.4 million.

  • Net revenue grew 46% to $9.5 million, surpassing pre-pandemic levels from Q3 2019 by 10%.
  • Laser system sales increased by 64%, indicating strong demand for BIOLASE's core products.
  • Gross margin improved significantly to 51%, up 1,600 basis points year-over-year, driven by higher revenue and favorable product mix.
  • U.S. and international revenue increased by 25% and 101%, respectively, reflecting recovery in dental practices.

Headline financials

Total Revenue

$9.53M

Previous: $6.54M+45.7%
EPS (adj)

-$0.54

Previous: -$0.25-116.0%
Capital Expenditures

$85K

Previous: -$3K+2933.3%
Free Cash Flow

-$3.68M

Previous: -$2.11M-75.0%
Net Income

-$3.3M

Previous: $12K-27600.0%
Operating Income

-$2.7M

Previous: -$3.67M+26.4%
Gross Profit

$4.84M

Previous: $2.27M+112.9%
Cash & Equivalents

$33.4M

Previous: $18.8M+77.2%
Total Assets

$58.5M

Previous: $42M+39.3%
Stock-Based Comp

$191K

Previous: $848K-77.5%

Revenue & EPS history

Biolase · Revenue · Quarterly

$9.53M

Q3 2021+45.7%vs Q3 2020
Beat estimate in 7 of 13 quarters(54%)
ActualEstimate

Revenue by segment

Biolase · $3.4M total across 1 segment · Q3 2021

  • US Laser Revenue
    $3.4M+25.9%

Forward guidance

The company expects significant year-over-year improvement across key performance metrics, including revenue and gross margin in the fourth quarter, and forecasts Q4 2021 revenue to be above the pre-pandemic revenue in Q4 2019 of $10.2 million.

Tailwinds

  • High demand for dental lasers.
  • Significant year-over-year improvement across key performance metrics.
  • Revenue expected to be above pre-pandemic levels.
  • Increased adoption across large and largely untapped markets.
  • BIOLASE lasers provide increased safety to dentists and their patients.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2021

Historical avgQ3 2021

-3.0%

Avg return

Earnings day

-6.6%

Avg return

5 days after

-13.5%

Avg return

30 days after

41%

24 / 58 earnings

Positive

+25.4%

Q2 2021

Best reaction

-45.7%

Q1 2020

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2024-18.9%-9.9%+26.1%
Q2 2024+7.8%-10.0%-30.0%
Q1 2024+1.8%-10.8%-21.9%
Q4 2024+20.3%+7.5%-6.8%
Q3 2023-22.0%-17.3%-23.4%
Q2 2023-19.5%-6.2%-50.2%
Q1 2023-6.7%-15.4%-17.4%
Q4 2022-10.8%-24.8%-43.8%
Q3 2022+16.3%+27.7%-49.2%
Q2 2022-1.1%-5.3%-33.6%
Q1 2022+0.0%-2.0%-47.1%
Q4 2021+2.9%+4.1%-9.3%
Q3 2021-8.2%-17.9%-34.5%
Q2 2021+25.4%+5.7%+10.0%
Q1 2021-1.2%-1.5%-10.8%
Q3 2020-3.3%-10.4%-0.8%
Q2 2020-2.4%-4.7%-28.9%
Q1 2020-45.7%-49.0%-6.0%
Q4 2019-22.4%-52.1%-7.3%
Q3 2019-5.8%+6.3%+2.9%
Q2 2019-7.7%-12.3%-36.1%
Q1 2019+2.5%-8.4%-13.9%
Q4 2018-16.5%-18.0%-21.6%
Q3 2018-9.3%-9.3%-27.9%
Q2 2018+9.5%+29.9%+60.6%
Q1 2018-2.4%+1.1%-13.1%
Q4 2017-4.1%-7.8%-36.7%
Q3 2017+0.0%+0.0%-25.0%
Q2 2017-29.8%-32.3%-28.8%
Q1 2017-3.8%-3.0%-3.8%
Q4 2016-2.5%-4.2%+5.8%
Q3 2016+20.8%+20.1%+18.8%
Q2 2016+1.8%+12.4%+56.6%
Q1 2016-12.3%
Q4 2015-0.8%
Q3 2015+8.5%
Q2 2015+6.3%
Q1 2015+1.0%
Q4 2014-2.5%
Q3 2014-3.3%
Q2 2014+1.4%
Q1 2014-0.8%
Q4 2013+0.7%
Q3 2013-11.8%
Q2 2013-22.7%
Q1 2013+3.5%
Q4 2012+1.0%
Q3 2012+10.6%
Q2 2012-1.2%
Q1 2011+0.8%
Q1 2012+1.8%
Q4 2011+0.5%
Q4 2009+0.5%
Q3 2011+4.9%
Q3 2010+4.9%
Q2 2010-10.2%
Q4 2010-10.2%
Q2 2011-10.2%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro